Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
David C. Hastings | Chief Financial Officer | 2025-02-04 | 22,183 | $3.28 | $72.83kSell |
Michael J. McElhaugh | Interim President CEO | 2025-02-04 | 23,790 | $3.28 | $78.10kSell |
J. Christopher Naftzger | General Counsel and CCO | 2025-02-04 | 11,333 | $3.28 | $37.21kSell |
Karen Sims | Chief Medical Officer | 2025-02-04 | 19,348 | $3.28 | $63.52kSell |
Keith S. Manchester | Director | 2024-08-14 | 8,846 | $3.69 | $32.63kSell |
Keith S. Manchester | Director | 2024-08-14 | 54,915 | $0.56 | $30.75kBuy |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Roivant Sciences Ltd | 20.28% | 38,847,462 | $137.13M | Insider |
Matthew Gline | 20.28% | 38,847,462 | $137.13M | Insider |
Dexxon Holdings Ltd | 16.72% | 32,027,080 | $113.06M | Insider |
Morgan Stanley | 12.42% | 23,792,389 | $83.99M | Institution |
Vivek Ramaswamy | 8.39% | 16,068,455 | $56.72M | Insider |
Viking Global Investors LP | 8.36% | 16,013,540 | $56.53M | Insider |
Viking Global Equities Master Ltd | 8.36% | 16,013,540 | $56.53M | Insider |
Dexcel Pharma Technologies Ltd | 8.36% | 16,013,540 | $56.53M | Insider |
Andrew Lo | 8.36% | 16,013,540 | $56.53M | Insider |
Viking Global Performance LLC | 8.36% | 16,013,540 | $56.53M | Insider |